Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 71Bevacizumab 64Carboplatin 56pembrolizumab 46olaparib 32Gemcitabine 29Specimen Handling 27Cyclophosphamide 26liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 21Taxes 19Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 13Disulfides 13Fulvestrant 12Blood Specimen Collection 11durvalumab 10Oxaliplatin 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × berzosertib × 1 year × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡